Anticancer Drugs Ipilimumab Oncology Pharmacology Physiotherapy

Ipilimumab (Mechanism of Action)

In this article we will discuss Ipilimumab (Mechanism of Action)

In this article, we will discuss Ipilimumab (Mechanism of Action). So, let’s get started.

Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.

Ipilimumab (YERVOY) is a sterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow
solution for intravenous infusion, which may contain a small amount of visible translucent-to-white, amorphous ipilimumab particulates. It is supplied in single-use vials of 50 mg/10 mL and 200 mg/40 mL. Each milliliter contains 5 mg of ipilimumab and the following inactive ingredients: diethylene triamine pentaacetic acid (DTPA) (0.04 mg), mannitol (10 mg), polysorbate 80 (vegetable origin) (0.1 mg), sodium chloride (5.85 mg), tris hydrochloride
(3.15 mg), and Water for Injection, USP at a pH of 7.

Mechanism of Action

CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CDS/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation
and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T cell responsiveness, including the anti-tumor immune response.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.